CIK 0001370053
- Non-accelerated filer
- Smaller reporting company
ANAPTYSBIO, INC
Sign in to watch- Ticker
- ANAB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 203828755
- Phone
- +1 858-362-6295
- Business address
- 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121
- Former names
- ANAPTYSBIO INC, ANAPTYS BIOSCIENCES INC
- Open-market buys, last 90 days
- $17,224,593
- in 1 filing
- Open-market sales, last 90 days
- $249,372
- in 1 filing, $249K under 10b5-1 plans
Net +$16,975,221. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-02-08 | Ware J. Anthony Director | Grant or award · Director Stock Option (Right to Buy) | +6,000 | 6,000 | ||
| 2019-02-08 | Topper James N Director | Grant or award · Director Stock Option (Right to Buy) | +6,000 | 6,000 | ||
| 2019-02-08 | Suria Hamza President, CEO | Grant or award · Employee Stock Option (Right to Buy) | −94,000 | 94,000 | ||
| 2019-02-08 | Schmid John P. Director | Grant or award · Director Stock Option (Right to Buy) | +6,000 | 6,000 | ||
| 2019-02-08 | RENTON HOLLINGS Director | Grant or award · Director Stock Option (Right to Buy) | +6,000 | 6,000 | ||
| 2019-02-08 | Piscitelli Dominic Chief Financial Officer | Grant or award · Employee Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2019-02-08 | Lydon Nicholas Director | Grant or award · Director Stock Option (Right to Buy) | +6,000 | 6,000 | ||
| 2019-02-08 | LOUMEAU ERIC J General Counsel | Grant or award · Employee Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2019-02-08 | Londei Marco Chief Medical Officer | Grant or award · Employee Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2019-02-08 | FENTON DENNIS M Director | Grant or award · Director Stock Option (Right to Buy) | +6,000 | 6,000 | ||
| 2019-01-15 | Londei Marco Chief Medical Officer | Exercise or conversion | +19,075 | $6.93 | $132K | 41,452 |
| 2019-01-15 | Londei Marco Chief Medical Officer | Sale | −4,181 | $69.29 | $290K | 37,271 |
| 2019-01-15 | Londei Marco Chief Medical Officer | Sale | −14,894 | $70.04 | $1.0M | 22,377 |
| 2019-01-15 | Londei Marco Chief Medical Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −19,075 | 51,148 | ||
| 2019-01-14 | Suria Hamza President, CEO | Exercise or conversion | +40,000 | $1.12 | $45K | 70,064 |
| 2019-01-14 | Suria Hamza President, CEO | Sale | −27,760 | $70.65 | $2.0M | 42,304 |
| 2019-01-14 | Suria Hamza President, CEO | Sale | −12,240 | $71.10 | $870K | 30,064 |
| 2019-01-14 | Suria Hamza President, CEO | Exercise or conversion · Employee Stock Option (Right to Buy) | −40,000 | 89,284 | ||
| 2018-12-26 | Londei Marco Chief Medical Officer | Gift | −122,500 | 22,377 | ||
| 2018-12-17 | Londei Marco Chief Medical Officer | Exercise or conversion | +8,048 | $0.70 | $6K | 152,925 |
Page 28 of 36 · 714 trades